P16 expression in squamous cell carcinomas of cervix and bladder

Maureen Cioffi-Lavina, Jennifer Chapman-Fredricks, Carmen Gomez-Fernandez, Parvin Ganjei-Azar, Murugesan Manoharan, Merce Jorda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Context/Objective: p16 is a widely used immunohistochemical marker in gynecologic pathology. Strong and diffuse cytoplasmic and nuclear expression of p16 in squamous cell carcinomas (SCC) of the female genital tract is strongly associated with high-risk human papilloma virus infection and neoplasms of cervical origin. However, p16 can be expressed in other neoplasms and in several normal human tissues. Occasionally, SCCs may involve both uterine cervix and urinary bladder. Accurate identification of the site of origin in such cases has therapeutic and prognostic implications. We investigate the potential value of p16 expression in this distinction. Design: We reviewed 74 SCCs, 38 (51%) from urinary bladder and 36 (49%) from uterine cervix obtained between 2003 and 2008. Of the 38 cases of bladder carcinoma, 21 occurred in females and 17 in males. Immunohistochemical analysis for p16 (DAKO M7247, clone 484, dilution of 1:50) expression was done in all cases using the labeled streptavidin-biotin method. RESULT: Strong and diffuse nuclear and cytoplasmic p16 positivity was observed in 45 cases (61%). Of the 38 SCCs of urinary bladder, 14 (37%) expressed p16 (8 males, 6 females). Of the 36 SCCs of uterine cervix, 31 (86%) were positive for p16. Conclusions: (1) The majority of SCCs of uterine cervix express p16. (2) More than a third of urinary bladder SCCs express p16. (3) SCCs of urinary bladder express p16 independent of gender. (4) p16 immunohistochemical expression alone cannot be used to discriminate between SCCs arising from uterine cervix versus urinary bladder.

Original languageEnglish
Pages (from-to)344-347
Number of pages4
JournalApplied Immunohistochemistry and Molecular Morphology
Volume18
Issue number4
DOIs
StatePublished - Jul 1 2010

Fingerprint

Cervix Uteri
Squamous Cell Carcinoma
Urinary Bladder
Papillomaviridae
Streptavidin
Virus Diseases
Biotin
Uterine Cervical Neoplasms
Clone Cells
Pathology
Carcinoma
Neoplasms

Keywords

  • dermatofibrosarcoma protuberans
  • gastric adenocarcinoma
  • Hodgkin and non-Hodgkin lymphomas
  • oncoprotein E7
  • p16
  • squamous cell carcinoma
  • urothelial carcinomas

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology

Cite this

P16 expression in squamous cell carcinomas of cervix and bladder. / Cioffi-Lavina, Maureen; Chapman-Fredricks, Jennifer; Gomez-Fernandez, Carmen; Ganjei-Azar, Parvin; Manoharan, Murugesan; Jorda, Merce.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 18, No. 4, 01.07.2010, p. 344-347.

Research output: Contribution to journalArticle

@article{1af2cd157e6848f3abb8688b11b60ccf,
title = "P16 expression in squamous cell carcinomas of cervix and bladder",
abstract = "Context/Objective: p16 is a widely used immunohistochemical marker in gynecologic pathology. Strong and diffuse cytoplasmic and nuclear expression of p16 in squamous cell carcinomas (SCC) of the female genital tract is strongly associated with high-risk human papilloma virus infection and neoplasms of cervical origin. However, p16 can be expressed in other neoplasms and in several normal human tissues. Occasionally, SCCs may involve both uterine cervix and urinary bladder. Accurate identification of the site of origin in such cases has therapeutic and prognostic implications. We investigate the potential value of p16 expression in this distinction. Design: We reviewed 74 SCCs, 38 (51{\%}) from urinary bladder and 36 (49{\%}) from uterine cervix obtained between 2003 and 2008. Of the 38 cases of bladder carcinoma, 21 occurred in females and 17 in males. Immunohistochemical analysis for p16 (DAKO M7247, clone 484, dilution of 1:50) expression was done in all cases using the labeled streptavidin-biotin method. RESULT: Strong and diffuse nuclear and cytoplasmic p16 positivity was observed in 45 cases (61{\%}). Of the 38 SCCs of urinary bladder, 14 (37{\%}) expressed p16 (8 males, 6 females). Of the 36 SCCs of uterine cervix, 31 (86{\%}) were positive for p16. Conclusions: (1) The majority of SCCs of uterine cervix express p16. (2) More than a third of urinary bladder SCCs express p16. (3) SCCs of urinary bladder express p16 independent of gender. (4) p16 immunohistochemical expression alone cannot be used to discriminate between SCCs arising from uterine cervix versus urinary bladder.",
keywords = "dermatofibrosarcoma protuberans, gastric adenocarcinoma, Hodgkin and non-Hodgkin lymphomas, oncoprotein E7, p16, squamous cell carcinoma, urothelial carcinomas",
author = "Maureen Cioffi-Lavina and Jennifer Chapman-Fredricks and Carmen Gomez-Fernandez and Parvin Ganjei-Azar and Murugesan Manoharan and Merce Jorda",
year = "2010",
month = "7",
day = "1",
doi = "10.1097/PAI.0b013e3181d2bbd7",
language = "English",
volume = "18",
pages = "344--347",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - P16 expression in squamous cell carcinomas of cervix and bladder

AU - Cioffi-Lavina, Maureen

AU - Chapman-Fredricks, Jennifer

AU - Gomez-Fernandez, Carmen

AU - Ganjei-Azar, Parvin

AU - Manoharan, Murugesan

AU - Jorda, Merce

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Context/Objective: p16 is a widely used immunohistochemical marker in gynecologic pathology. Strong and diffuse cytoplasmic and nuclear expression of p16 in squamous cell carcinomas (SCC) of the female genital tract is strongly associated with high-risk human papilloma virus infection and neoplasms of cervical origin. However, p16 can be expressed in other neoplasms and in several normal human tissues. Occasionally, SCCs may involve both uterine cervix and urinary bladder. Accurate identification of the site of origin in such cases has therapeutic and prognostic implications. We investigate the potential value of p16 expression in this distinction. Design: We reviewed 74 SCCs, 38 (51%) from urinary bladder and 36 (49%) from uterine cervix obtained between 2003 and 2008. Of the 38 cases of bladder carcinoma, 21 occurred in females and 17 in males. Immunohistochemical analysis for p16 (DAKO M7247, clone 484, dilution of 1:50) expression was done in all cases using the labeled streptavidin-biotin method. RESULT: Strong and diffuse nuclear and cytoplasmic p16 positivity was observed in 45 cases (61%). Of the 38 SCCs of urinary bladder, 14 (37%) expressed p16 (8 males, 6 females). Of the 36 SCCs of uterine cervix, 31 (86%) were positive for p16. Conclusions: (1) The majority of SCCs of uterine cervix express p16. (2) More than a third of urinary bladder SCCs express p16. (3) SCCs of urinary bladder express p16 independent of gender. (4) p16 immunohistochemical expression alone cannot be used to discriminate between SCCs arising from uterine cervix versus urinary bladder.

AB - Context/Objective: p16 is a widely used immunohistochemical marker in gynecologic pathology. Strong and diffuse cytoplasmic and nuclear expression of p16 in squamous cell carcinomas (SCC) of the female genital tract is strongly associated with high-risk human papilloma virus infection and neoplasms of cervical origin. However, p16 can be expressed in other neoplasms and in several normal human tissues. Occasionally, SCCs may involve both uterine cervix and urinary bladder. Accurate identification of the site of origin in such cases has therapeutic and prognostic implications. We investigate the potential value of p16 expression in this distinction. Design: We reviewed 74 SCCs, 38 (51%) from urinary bladder and 36 (49%) from uterine cervix obtained between 2003 and 2008. Of the 38 cases of bladder carcinoma, 21 occurred in females and 17 in males. Immunohistochemical analysis for p16 (DAKO M7247, clone 484, dilution of 1:50) expression was done in all cases using the labeled streptavidin-biotin method. RESULT: Strong and diffuse nuclear and cytoplasmic p16 positivity was observed in 45 cases (61%). Of the 38 SCCs of urinary bladder, 14 (37%) expressed p16 (8 males, 6 females). Of the 36 SCCs of uterine cervix, 31 (86%) were positive for p16. Conclusions: (1) The majority of SCCs of uterine cervix express p16. (2) More than a third of urinary bladder SCCs express p16. (3) SCCs of urinary bladder express p16 independent of gender. (4) p16 immunohistochemical expression alone cannot be used to discriminate between SCCs arising from uterine cervix versus urinary bladder.

KW - dermatofibrosarcoma protuberans

KW - gastric adenocarcinoma

KW - Hodgkin and non-Hodgkin lymphomas

KW - oncoprotein E7

KW - p16

KW - squamous cell carcinoma

KW - urothelial carcinomas

UR - http://www.scopus.com/inward/record.url?scp=77954092218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954092218&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e3181d2bbd7

DO - 10.1097/PAI.0b013e3181d2bbd7

M3 - Article

C2 - 20571342

AN - SCOPUS:77954092218

VL - 18

SP - 344

EP - 347

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 4

ER -